Home > Search Results: pozniak
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 4 records in 0.02 seconds.
Articles, 4 records found
Articles 4 records found  
1.
12 p, 608.0 KB Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk / Gatell, José Mª (Hospital Clínic i Provincial de Barcelona) ; Assoumou, Lambert (UPMC Univ Paris 06) ; Moyle, Graeme (St Chelsea and Westminster Hospital) ; Waters, Laura (Mortimer Market Center) ; Johnson, Margaret (Royal Free Hospital) ; Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ; Fox, Julie (Guys and St. Thomas Hospital) ; Martinez, Esteban (Hospital Clínic i Provincial de Barcelona) ; Stellbrink, Hans-Jürgen (ICH Study Centrum) ; Guaraldi, Giovanni (University of Modena and Reggio Emilia) ; Masia, Mar (Hospital General Universitario de Elche) ; Gompels, Marl (Southmead Hospital) ; De Wit, Stephane (Université Libre de Bruxelles) ; Florence, Eric (Institute of Tropical Medicine) ; Esser, Stefan (Universitatsklinikum) ; Raffi, François (CHU de Nantes) ; Pozniak, Anton L. (St Chelsea and Westminster Hospital) ; Universitat Autònoma de Barcelona
To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. [...]
2017 - 10.1097/QAD.0000000000001675
AIDS, Vol. 31 Núm. 18 (28 2017) , p. 2503-2514  
Detailed record - Creative Commons
2.
10 p, 271.5 KB Patient self-reported adherence to ritonavir-boosted darunavir combined with either raltegravir or tenofovir disoproxil fumarate/emtricitabine in the NEAT001/ANRS143 Trial / Ammassari, Adriana (IRCCS) ; Stöhr, Wolfgang (Medical Research Council Clinical Trials Unit at UCL) ; Antinori, Andrea (IRCCS) ; Molina, Jean-Michel (University of Paris Diderot) ; Schwimmer, Christine (University of Bordeaux) ; Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ; Thalme, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Di Pietro, Massimo (S. Maria Annunziata Hospital) ; Wallet, Cedrik (University of Bordeaux) ; Pozniak, Anton (Chelsea and Westminster NHS Trust St Stephens Centre) ; Richert, Laura (University of Bordeaux) ; Raffi, François (INSERM CIC 1413. CHU) ; Universitat Autònoma de Barcelona
NEAT001/ANRS143 trial demonstrated noninferiority of ritonavir-boosted darunavir combined with either raltegravir (RAL + DRV/r) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC + DRV/r) in HIV-positive, antiretroviral-naive adults. [...]
2018 - 10.1097/QAI.0000000000001834
Journal of Acquired Immune Deficiency Syndromes, Vol. 79 Núm. 4 (2018) , p. 481-490  
Detailed record - Creative Commons
3.
1 p, 76.1 KB Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure / Schultze, Anna (Department of Infection and Population Health, University College London, UK) ; Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Sabin, Caroline (Department of Infection and Population Health, University College London, UK) ; Phillips, Andrew N. (Department of Infection and Population Health, University College London, UK) ; Pillay, Deenan (Department of Infection and Population Health, University College London, UK) ; Kirk, Ole (Copenhagen University Hospital Rigshospitalet, Denmark) ; Lundgren, Jens D. (Copenhagen University Hospital Rigshospitalet, Denmark) ; Pozniak, Anton (HIV and Sexual Health - Kobler Clinic, Chelsea and Westminster Hospital, London, UK) ; Nelson, Mark (HIV and Sexual Health - Kobler Clinic, Chelsea and Westminster Hospital, London, UK) ; Cozzi-Lepri, Alessandro (University College London, UK) ; Universitat Autònoma de Barcelona. Departament de Medicina
Several resistance mutations have been shown to affect viral fitness, and the presence of certain mutations might result in clinical benefit for patients kept on a virologically failing regimen due to an exhaustion of drug options. [...]
2014 - 10.7448/IAS.17.4.19737
Journal of the International AIDS Society, Vol. 17 (november 2014)  
Detailed record - Creative Commons
4.
11 p, 844.7 KB Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals / Kawana-Tachikawa, Ai (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Llibre, Josep M.. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Bravo, Isabel (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Escrig, Roser (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Mothe, Beatriz (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Puig, Jordi (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Puertas, Maria C. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Martinez-Picado, Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Manzardo, Christian (Hospital Clínic i Provincial de Barcelona) ; Miro, Jose M. (Hospital Clínic i Provincial de Barcelona) ; Iwamoto, Aikichi (The Institute of Medical Science, The University of Tokyo, Japan) ; Pozniak, Anton L. (HIV/GUM Department, Chelsea and Westminster Hospital, London, United Kingdom) ; Gatell, Jose M. (Hospital Clínic i Provincial de Barcelona) ; Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Brander, Christian (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Universitat Autònoma de Barcelona. Departament de Medicina
The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. [...]
2014 - 10.1371/journal.pone.0087334
PloS one, Vol. 9 (january 2014)  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with